MB Therapeutics
MB Therapeutics is developing personalized 3D printed medications that offer customized dosages and improved drug administration, particularly for pediatric patients.
- CEO / Founder
- Stéphane Roulon
- Team Size
- 1-10
- Stage
- Active
- Total Funding
- €2M
- Latest Round
- Seed
- Key Investors
- Beprep, Calyseed, Angels Sante
Technology & Products
Key Products
Personalized 3D printed medications for customized dosages and improved drug administration, particularly for pediatric patients.
Technological Advantage
Ability to produce customized dosages and integrate multiple drugs into a single pill.
Differentiation
Value Proposition
Customized drug dosages with improved administration enabled by 3D printing and GMP-certified manufacturing.
How They Differentiate
Focused on pediatric care and combining GMP-certified manufacturing with innovative 3D printing technology.
Market & Competition
Target Customers
Pediatric care providers and patients
Industry Verticals
["Pharmaceuticals","Pediatric care"]
Competitors
Aprecia Pharmaceuticals; FabRx; Doser
Growth & Milestones
Growth Metrics
Raised €2 million in funding, led by Beprep, Calyseed, Angels Santé, BPI, and business angels including Sébastien Gallice. Plans to launch three high-demand medicines and pursue Series A funding in 2026. Supported by BIC 3M, AD'OCC region, and BPI.
Major Milestones
["Expansion of leadership team with Damien Stefanelli as COO","Participation in GERPAC 2024 to showcase innovations"]
Notable Customers
University Hospital Center of Nîmes; Sanofi